PE20040204A1 - ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION - Google Patents
ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATIONInfo
- Publication number
- PE20040204A1 PE20040204A1 PE2003000195A PE2003000195A PE20040204A1 PE 20040204 A1 PE20040204 A1 PE 20040204A1 PE 2003000195 A PE2003000195 A PE 2003000195A PE 2003000195 A PE2003000195 A PE 2003000195A PE 20040204 A1 PE20040204 A1 PE 20040204A1
- Authority
- PE
- Peru
- Prior art keywords
- integrin alpha
- disease
- treatment
- dimmer
- refers
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title abstract 3
- 230000004054 inflammatory process Effects 0.000 title abstract 3
- 102100032818 Integrin alpha-4 Human genes 0.000 abstract 3
- 108010041012 Integrin alpha4 Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229960005027 natalizumab Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN METODO PARA REDUCIR DE MANERA CRONICA LA INFLAMACION PATOLOGICA QUE CONSISTE EN ADMINISTRAR UN AGENTE QUE INHIBE A LA INTEGRINA ALFA-4 O UN DIMERO QUE COMPRENDE INTEGRINA ALFA-4; MEDIANTE UNA INFUSION INTRAVENOSA EN LA CANTIDAD DE ALREDEDOR DE 1 MG/KG A 20 MG/KG DEL PACIENTE CADA CUATRO SEMANAS DURANTE UN PERIODO DE AL MENOS 6 MESES DE MANERA REPETIDA MANTENIENDO LA SATURACION DE RECEPTORES DE INTEGRINA EN AL MENOS ALREDEDOR DE 65 % A 100%, SIENDO EL AGENTE UN ANTICUERPO MONOCLONAL O UN FRAGMENTO DEL MISMO INMUNOLOGICAMENTE ACTIVO ES NATALIZUMAB Y EL DIMERO DE INTEGRINA ALFA-4 ES ALFA-4-BETA-1.TAMBIEN SE REFIERE A UNA COMPOSICION. SE PUEDE UTILIZAR PARA EL TRATAMIENTO DE INFLAMACION PATOLOGICA QUE ES CAUSADA POR ESCLEROSIS MULTIPLE, ENFERMEDAD INFLAMATORIA DEL TRACTO GASTRO INTESTINALTAL COMO ENFERMEDAD DE CROHN, COLITIS ULCEROSA O ENFERMEDAD INFLAMATORIA INTESTINALREFERS TO A METHOD TO CHRONICALLY REDUCE PATHOLOGICAL INFLAMMATION WHICH CONSISTS OF ADMINISTERING AN AGENT THAT INHIBITS INTEGRIN ALPHA-4 OR A DIMMER THAT INCLUDES INTEGRIN ALPHA-4; BY AN INTRAVENOUS INFUSION IN THE AMOUNT OF AROUND 1 MG / KG TO 20 MG / KG OF THE PATIENT EVERY FOUR WEEKS DURING A PERIOD OF AT LEAST 6 MONTHS IN A REPEATED MANNER, KEEPING THE SATURATION OF RECEPTORS OF INTEGRED A AT LEAST 65% 100%, WHERE THE AGENT IS A MONOCLONAL ANTIBODY OR AN IMMUNOLOGICALLY ACTIVE FRAGMENT OF THE SAME IS NATALIZUMAB AND THE DIMMER OF INTEGRIN ALPHA-4 IS ALPHA-4-BETA-1 ALSO REFERS TO A COMPOSITION. IT CAN BE USED FOR THE TREATMENT OF PATHOLOGICAL INFLAMMATION WHICH IS CAUSED BY MULTIPLE SCLEROSIS, INFLAMMATORY DISEASE OF THE GASTRO INTESTINAL TRACT SUCH AS CROHN'S DISEASE, ULCEROUS COLITIS OR INFLAMMATORY BOWEL DISEASE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37450102P | 2002-04-23 | 2002-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040204A1 true PE20040204A1 (en) | 2004-04-08 |
Family
ID=38813807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000195A PE20040204A1 (en) | 2002-04-23 | 2003-02-27 | ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION |
Country Status (2)
| Country | Link |
|---|---|
| PE (1) | PE20040204A1 (en) |
| UY (1) | UY27688A1 (en) |
-
2003
- 2003-02-27 PE PE2003000195A patent/PE20040204A1/en not_active Application Discontinuation
- 2003-02-27 UY UY27688A patent/UY27688A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY27688A1 (en) | 2003-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002592A1 (en) | Use of agents for treatment of respiratory conditions | |
| CO5650245A2 (en) | DISPERSABLE FORMULATIONS OF AN ANTI-INFLAMMATORY AGENT | |
| CO5611176A2 (en) | ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION | |
| HRP20230929T1 (en) | Stable semaglutide compositions and uses thereof | |
| PE20230819A1 (en) | COMPOSITIONS AND USES OF GLP-1 | |
| NZ609719A (en) | Pharmaceutical composition | |
| EA200000468A1 (en) | THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY | |
| AR049985A1 (en) | COMBINATION TREATMENT FOR NON-HEMATOLOGICAL MALIGNAL DISEASES | |
| BRPI0506705A (en) | composed of azabenzofuran-substituted thioureas, pharmaceutical compositions and their uses | |
| DE60327843D1 (en) | MEDICAMENT FORMULATIONS WITH DELAYED RELEASE WITH A CARRIER PEPTIDE | |
| RU2014127298A (en) | APPLICATIONS OF IMMUNO CONJUGATES WHICH ARE THE TARGET OF CD138 | |
| EE200200107A (en) | Use of a fast-acting selective serotonin reuptake inhibitor in the manufacture of a medicament for the treatment of sexual dysfunction | |
| EA200700214A1 (en) | MEMANTINE AS AN ADDITIONAL THERAPY FOR ATYPICAL ANTIPSYCHOTIC REMEDIES IN PATIENTS WITH SCHIZOPHRENIA | |
| EA201992759A1 (en) | ASSOCIATION INCLUDING OXYGEN AND HYALURONIC ACID, FOR LOCAL VAGINAL USE | |
| ES2149733T1 (en) | ORAL PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE CONTAINING 5-ASA AND METHOD FOR THE TREATMENT OF INTESTINAL DISEASES. | |
| MX2025005378A (en) | Methods for the treatment of cardiovascular disease | |
| Ch'en | Demonstration of macrofilaricidal action of Hetrazan, antimony and arsenic preparations in man | |
| AR068531A1 (en) | FIXED DOSE BY ONE INJECTION FOR OCRELIZUMAB (2H7). USE OF RITUXIMAB. PHARMACEUTICAL FORMULATION KIT | |
| AR069767A1 (en) | TREATMENT OF MELANOMA WITH ALPHA TIMOSINE PEPTIDES IN COMBINATION WITH ENTINEOPLASTIC THERMAL SHOCK APOPTOSIS ACTIVATOR (HSAA) | |
| AR048806A1 (en) | USE OF CARIOFILENES IN THE PREPARATION OF MEDICINES AND TREATMENT OF BODY INFLAMMATION AND INFLAMMATORY PAIN AFFECTIONS | |
| PE20040204A1 (en) | ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION | |
| Zweig et al. | Rectal administration of propylthiouracil in suppository form in patients with thyrotoxicosis and critical illness: case report and review of literature | |
| Winning et al. | Case report: nitazoxanide for treatment of refractory bony hydatid disease | |
| NO20055390L (en) | Thorium-227 for use in radiotherapy in soft tissue diseases | |
| WO2024112527A3 (en) | Methods for the treatment of thyroid eye disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |